Cross-border M&A is reglobalising: what changes for a private seller
Cross-border deals keep flowing, but along new corridors and under longer reviews. For owners selling to a foreign buyer, the corridor now shapes price, timing and certainty.
Cross-border M&A has not slowed down; it has changed direction. Capital is still crossing borders in size, but it is following supply chains, security concerns and political alignment rather than the cheapest cost base. For an owner selling a privately held company to a foreign buyer, that shift matters as much as the multiple. Which buyer, from which country, under which review, now decides how long a deal takes and how likely it is to close.
The numbers behind the shift
Mergermarket data published by ION Analytics on 23 October puts cross-border dealmaking in the first nine months of 2026 at USD 1.2 trillion. Inbound M&A into the United States rose 4% over the same period, to 1,109 transactions worth USD 295.5 billion.
The more telling figures are about where the money is going. The same report notes a 20% increase in M&A targeting Mexico and Poland, the two clearest near-shoring hubs for the US and European markets, with Poland recording the fourth-largest aggregate inbound deal volume in Europe. Inbound investment into the United Kingdom doubled, as buyers used it as an entry point to Europe.
The report also shows how sensitive activity remains to shocks. Global M&A volume fell 7% in the quarters after the US tariff announcements of April 2025 and 29% after the Iran conflict earlier this year. Deals did not disappear in either case; they were delayed and repriced.
The corridor a buyer comes from now carries as much weight in a cross-border sale as the price it offers.
What reglobalisation means in a sale process
The term used in the report, reglobalisation, is useful because it is not deglobalisation. Trade and investment continue, but along routes that governments and boards consider safe. Three practical consequences follow for a seller.
The buyer list changes shape
A company that sits inside a near-shoring corridor, such as a Mexican component supplier or a Polish logistics operator, can attract strategic buyers that would not have looked at it five years ago. Buyers from allied jurisdictions may pay for supply-chain resilience, not only for earnings. The seller's job is to understand which buyers value that resilience and to build the process around them, not around a generic list of trade buyers and sponsors.
Review time becomes a pricing variable
Foreign investment screening has widened in most major economies, and merger control in Europe and elsewhere is reaching more deals. A higher offer from a buyer facing a long or uncertain review can be worth less than a lower offer from a buyer who can close in a quarter. Sellers increasingly compare offers on a time-adjusted, risk-adjusted basis: price, expected closing date and the probability of clearance, read together.
Certainty has to be written into the contract
When timelines stretch, the risk of a deal stalling between signing and closing grows. That risk is allocated in the purchase agreement: long-stop dates, reverse break fees payable if regulatory approval fails, undertakings on what remedies a buyer will accept, and covenants on how the business is run while it waits. A seller who negotiates price hard and these clauses lightly can end up with a headline number and no deal.
A hypothetical comparison
Consider, as a purely hypothetical example, a family-owned manufacturer in northern Mexico with two offers. Buyer A, from a jurisdiction that triggers a detailed national-security review in a key market, offers 10% more. Buyer B, a regional strategic with no screening exposure, offers less but expects to close in four months.
If Buyer A's review could take a year, the seller carries operating risk, management distraction and the chance of a failed process for that whole period. A reverse break fee and a firm commitment to accept reasonable remedies could make Buyer A's offer the better one. Without them, the 10% premium may not survive a sober comparison. The point is not which buyer wins, but that the comparison has to be made explicitly.
Questions to ask
- Which approvals, in which countries, does each bidder trigger, and what is a realistic timetable for each?
- Is the price premium from a higher-risk bidder larger than the cost of a delayed or failed closing?
- What long-stop date, reverse break fee and remedies undertaking is each buyer prepared to sign?
- How does the business's position in a near-shoring or allied supply chain show up in the buyer's own investment case?
- How would a renewed trade dispute between the buyer's and the target's countries affect the deal before closing?
Sources
Informational content only. Not investment advice.